Financings Routine +

Charlotte's Web Announces Closing of Transaction with British American Tobacco, Including US$10 Million Investment

Charlotte's Web Closes BAT Deal, Eliminating Debt Overhang but Facing Dilution and Revenue Headwinds

By The Northwire Desk — AI Analysis May 28, 2026 · 19:34 CWEB · 0.7 CHARLOTTE'S WEB HOLDINGS, INC.

Executive Summary

Charlotte's Web Holdings, Inc. has officially closed its transaction with British American Tobacco (BAT) subsidiary BT DE Investments Inc.
The deal involved converting approximately C$89.6 million in outstanding convertible debentures and accrued interest into common shares at a conversion price of C$0.94 per share.
Concurrently, BAT invested US$10 million in new cash proceeds via a private placement equity investment at the same subscription price of C$0.94 per share.
Total shares issued to BAT amount to 109,944,042 common shares, representing approximately 40.6% ownership of the combined company post-closing.
Proceeds from the private placement will support participation in the anticipated CMMI Medicare pilot program and other medical channel initiatives.
The transaction is subject to final approval from the Toronto Stock Exchange (TSX), which appears to have been satisfied given the closing announcement.

Material Impact

Debt Elimination: The conversion removes approximately US$65 million in debt liability, significantly strengthening the balance sheet and eliminating ~US$3 million in annual interest costs plus ~US$12 million in future interest through 2029. This is a critical solvency improvement.
Dilution Risk: BAT now holds ~40% of outstanding shares. While this provides strategic backing, it represents massive dilution for existing shareholders and limits upside potential unless BAT drives significant value creation.
Market Expectations: The transaction was announced in March 2026 (NewsId 48016) and approved by shareholders on May 28, 2026 (NewsId 2496565). The closing news confirms execution of a known plan rather than introducing new information.
Stock Price Reaction: The stock has traded significantly lower from its February peak ($1.29) to the current level ($0.70), suggesting the market may have already priced in the dilution and debt conversion benefits months ago.
Operational Context: Q1 2026 revenue declined to $11.2 million (down from $12.3 million YoY). The financing does not immediately address top-line growth, which remains a concern despite balance sheet repair.

CWEB · Price

Company Overview

Company: Charlotte's Web Holdings, Inc. (CWEB/CWBHF).
Flagship Project: DeFloria Phase 2 clinical trial for AJA001 oral solution targeting irritability associated with autism spectrum disorder (ASD).
Core Business: CBD/Hemp-derived wellness products including oils, gummies, and topicals under the Charlotte's Web and Brightside brands.
Strategic Pivot: Transitioning from consumer CBD to medical channel reimbursement via Medicare/Medicaid pilot programs and pharmaceutical drug development.

More from CHARLOTTE'S WEB HOLDINGS, INC.